Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer-Reference-Cited by-同舟云学术

Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer

Published:2003-06 Issue:6 Volume:169 Page:2008-2012
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

SMITH MATTHEW R.¹,EASTHAM JAMES¹,GLEASON DONALD M.¹,SHASHA DANIEL¹,TCHEKMEDYIAN SIMON¹,ZINNER NORMAN¹

Affiliation:

1. From Massachusetts General Hospital, Boston, Massachusetts, Overtone Brooks Veterans’ Administration Medical Center, Shreveport, Louisiana, Advanced Clinical Therapeutics, Tucson, Arizona, Beth Israel Medical Center, New York, New York, Pacific Shores Medical Group, Long Beach, and Western Clinical Research, Torrence, California

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference10 articles.

1. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer;Ross;J Urol,2002

2. Skeletal fractures negatively correlate with overall survival in men with prostate cancer;Oefelein;J Urol,2002

3. Intravenous zoledronic acid in postmenopausal women with low bone mineral density;Reid;N Engl J Med,2002

4. Assessing bone density in men;Orwoll;J Bone Miner Res,2000

5. Low bone mineral density in hormone-naive men with prostate carcinoma;Smith;Cancer,2001

Cited by 557 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials;Radiotherapy and Oncology;2024-06

2. Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience;Clinical and Experimental Medicine;2024-01-19

3. Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2023-11-01

4. Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer;Journal of Bone and Mineral Metabolism;2023-04-10

5. Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications;Cancers;2023-02-28